Sanofi (NASDAQ:SNY) Shares Sold by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC cut its stake in Sanofi (NASDAQ:SNY) by 2.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,648 shares of the company’s stock after selling 488 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Sanofi were worth $808,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of SNY. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the 2nd quarter valued at about $25,000. Register Financial Advisors LLC purchased a new stake in shares of Sanofi in the first quarter valued at approximately $29,000. Larson Financial Group LLC increased its position in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Sanofi during the 4th quarter worth approximately $31,000. Finally, Palisade Asset Management LLC acquired a new stake in Sanofi in the 1st quarter valued at $31,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $57.43 on Tuesday. The company has a market cap of $145.45 billion, a P/E ratio of 28.86, a P/E/G ratio of 1.62 and a beta of 0.60. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97. The company’s 50-day moving average price is $54.34 and its 200-day moving average price is $50.52. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the previous year, the firm posted $0.95 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, sell-side analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

SNY has been the subject of a number of research analyst reports. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Friday. Finally, Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.